132 related articles for article (PubMed ID: 23924586)
1. Randomized trial to evaluate cardiometabolic and endothelial function in patients with plasma HIV-1 RNA suppression switching to darunavir/ritonavir with or without nucleoside analogues.
Guaraldi G; Zona S; Cossarizza A; Vernacotola L; Carli F; Lattanzi A; Beghetto B; Orlando G; De Biasi S; Termini R; Garau M
HIV Clin Trials; 2013; 14(4):140-8. PubMed ID: 23924586
[TBL] [Abstract][Full Text] [Related]
2. The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load < 50 HIV-1 RNA copies/mL at baseline.
Arribas JR; Clumeck N; Nelson M; Hill A; van Delft Y; Moecklinghoff C
HIV Med; 2012 Aug; 13(7):398-405. PubMed ID: 22413874
[TBL] [Abstract][Full Text] [Related]
3. Week 96 efficacy and safety of darunavir/ritonavir monotherapy vs. darunavir/ritonavir with two nucleoside reverse transcriptase inhibitors in the PROTEA trial.
Girard PM; Antinori A; Arribas JR; Ripamonti D; Bicer C; Netzle-Sveine B; Hadacek B; Moecklinghoff C
HIV Med; 2017 Jan; 18(1):5-12. PubMed ID: 27279571
[TBL] [Abstract][Full Text] [Related]
4. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial.
Orkin C; DeJesus E; Khanlou H; Stoehr A; Supparatpinyo K; Lathouwers E; Lefebvre E; Opsomer M; Van de Casteele T; Tomaka F
HIV Med; 2013 Jan; 14(1):49-59. PubMed ID: 23088336
[TBL] [Abstract][Full Text] [Related]
5. The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml.
Arribas JR; Horban A; Gerstoft J; Fätkenheuer G; Nelson M; Clumeck N; Pulido F; Hill A; van Delft Y; Stark T; Moecklinghoff C
AIDS; 2010 Jan; 24(2):223-30. PubMed ID: 20010070
[TBL] [Abstract][Full Text] [Related]
6. Subgroup analysis of virological response rates with once- and twice-daily darunavir/ritonavir in treatment-experienced patients without darunavir resistance-associated mutations in the ODIN trial.
Sension M; Cahn P; Domingo P; Hodder S; Opsomer M; Lathouwers E; Van de Casteele T; Tomaka F
HIV Med; 2013 Aug; 14(7):437-44. PubMed ID: 23480640
[TBL] [Abstract][Full Text] [Related]
7. Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients.
Cahn P; Fourie J; Grinsztejn B; Hodder S; Molina JM; Ruxrungtham K; Workman C; Van De Casteele T; De Doncker P; Lathouwers E; Tomaka F
AIDS; 2011 Apr; 25(7):929-39. PubMed ID: 21346512
[TBL] [Abstract][Full Text] [Related]
8. Dynamics of cellular HIV-1 DNA levels over 144 weeks of darunavir/ritonavir monotherapy versus triple therapy in the MONET trial.
Geretti AM; Arribas JR; Lathouwers E; Foster GM; Yakoob R; Kinloch S; Hill A; van Delft Y; Moecklinghoff C
HIV Clin Trials; 2013; 14(1):45-50. PubMed ID: 23372114
[TBL] [Abstract][Full Text] [Related]
9. 96 week results from the MONET trial: a randomized comparison of darunavir/ritonavir with versus without nucleoside analogues, for patients with HIV RNA <50 copies/mL at baseline.
Clumeck N; Rieger A; Banhegyi D; Schmidt W; Hill A; Van Delft Y; Moecklinghoff C; Arribas J
J Antimicrob Chemother; 2011 Aug; 66(8):1878-85. PubMed ID: 21652619
[TBL] [Abstract][Full Text] [Related]
10. Analysis of drug resistance during HIV RNA viraemia in the MONET trial of darunavir/ritonavir monotherapy.
Pulido F; Arribas JR; Hill A; Van Delft Y; Moecklinghoff C
Antivir Ther; 2011; 16(1):59-65. PubMed ID: 21311109
[TBL] [Abstract][Full Text] [Related]
11. Simplification from twice-daily to once-daily darunavir/ritonavir in a randomized trial among HIV-infected persons with HIV-1 RNA suppression on antiretroviral therapy.
Huhn GD; Sigman A; Livak B
Antivir Ther; 2015; 20(8):849-54. PubMed ID: 25881614
[TBL] [Abstract][Full Text] [Related]
12. Switching to darunavir/ritonavir monotherapy vs. triple-therapy on body fat redistribution and bone mass in HIV-infected adults: the Monarch randomized controlled trial.
Guaraldi G; Zona S; Cossarizza A; Vernacotola L; Carli F; Lattanzi A; Nardini G; Orlando G; Garlassi E; Termini R; Garau M
Int J STD AIDS; 2014 Mar; 25(3):207-12. PubMed ID: 24216034
[TBL] [Abstract][Full Text] [Related]
13. The PROTEA trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV-1 RNA below 50 copies/mL.
Antinori A; Arribas J; Fehr J; Girard PM; Horban A; Hill A; van Delft Y; Moecklinghoff C; Hill A
J Int AIDS Soc; 2014; 17(4 Suppl 3):19525. PubMed ID: 25394034
[TBL] [Abstract][Full Text] [Related]
14. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.
Mills AM; Nelson M; Jayaweera D; Ruxrungtham K; Cassetti I; Girard PM; Workman C; Dierynck I; Sekar V; Abeele CV; Lavreys L
AIDS; 2009 Aug; 23(13):1679-88. PubMed ID: 19487905
[TBL] [Abstract][Full Text] [Related]
15. Body fat distribution in HIV-infected patients treated for 96 weeks with darunavir/ritonavir monotherapy versus darunavir/ritonavir plus nucleoside reverse transcriptase inhibitors: the MONOI-ANRS136 substudy.
Valantin MA; Kolta S; Flandre P; Algarte Genin M; Meynard JL; Ponscarme D; Slama L; Cuzin L; de Kerviler E; Inaoui R; Katlama C
HIV Med; 2012 Sep; 13(8):505-15. PubMed ID: 22416798
[TBL] [Abstract][Full Text] [Related]
16. Virological analysis of once-daily and twice-daily darunavir/ritonavir in the ODIN trial of treatment-experienced patients.
Lathouwers E; De La Rosa G; Van de Casteele T; Baeten B; Tomaka F; De Meyer S; Picchio G
Antivir Ther; 2013; 18(3):289-300. PubMed ID: 23558157
[TBL] [Abstract][Full Text] [Related]
17. Week 48 efficacy and central nervous system analysis of darunavir/ritonavir monotherapy versus darunavir/ritonavir with two nucleoside analogues.
Antinori A; Clarke A; Svedhem-Johansson V; Arribas JR; Arenas-Pinto A; Fehr J; Gerstoft J; Horban A; Clotet B; Ripamonti D; Girard PM; Hill AM; Moecklinghoff C
AIDS; 2015 Sep; 29(14):1811-20. PubMed ID: 26372387
[TBL] [Abstract][Full Text] [Related]
18. A 48-week pilot study switching suppressed patients to darunavir/ritonavir and etravirine from enfuvirtide, protease inhibitor(s), and non-nucleoside reverse transcriptase inhibitor(s).
Ruane P; Alas B; Ryan R; Perniciaro A; Witek J
AIDS Res Hum Retroviruses; 2010 Nov; 26(11):1215-9. PubMed ID: 21083412
[TBL] [Abstract][Full Text] [Related]
19. Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks.
Aberg JA; Tebas P; Overton ET; Gupta SK; Sax PE; Landay A; Falcon R; Ryan R; De La Rosa G
AIDS Res Hum Retroviruses; 2012 Oct; 28(10):1184-95. PubMed ID: 22352336
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of once-daily maraviroc plus ritonavir-boosted darunavir in pretreated HIV-infected patients in a real-life setting.
Macías J; Recio E; Márquez M; García C; Jiménez P; Merino D; Muñoz L; Pasquau J; Ojeda G; Bancalero P; Chueca N; Pineda JA
HIV Med; 2014 Aug; 15(7):417-24. PubMed ID: 24580801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
